Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 9/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246309 | 0.96 | SCD (0.54) | SCDALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL241064 | 0.96 | SCD (0.56) | SCDALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL243342 | 0.95 | SCD (0.57) | SCDALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL241656 | 0.93 | SCD (0.49) | SCDALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL243521 | 0.89 | SCD (0.47) | SCDALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL244610 | 0.87 | ALDH1A1 (0.52) | SCDALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL244565 | 0.86 | SCD (0.59) | SCDALDH1A1HPGDTSHR | |
| SCHEMBL347922 | 0.86 | SCD (0.59) | SCDALDH1A1MAPTGAA | |
| SCHEMBL349319 | 0.85 | SCD (0.45) | SCDALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL347155 | 0.85 | SCD (0.61) | SCDALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054408-B1 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2054408-B1 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level | NOVARTIS AG (CH) | 2016-07-13 | — | — | EP | disclosed |
| EP-2245029-B1 | HETEROCYCLIC INHIBITORS OF STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| EP-2245029-B1 | HETEROCYCLIC INHIBITORS OF STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-8318949-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| EP-2054408-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | Novartis Ag (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-7479515-B2 | Polypropylene resin compositions | CIBA SPECIALTY CHEMICALS CORP. (US) | 2009-01-20 | — | — | US | disclosed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127349-A2 | HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DISEASES RELATED TO ELEVATED LIPID LEVEL | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| US-20070170398-A1 | Polypropylene resin compositions | SCHMIDT HANS-WERNER | 2007-07-26 | — | — | US | disclosed |
| US-7235191-B2 | Crystallizable polypropylene homopolymer, random copolymer, alternating or segmented copolymer, block copolymer or a blend of polypropylene with another synthetic polymer, and b) 0.001 to 5% relative to the weight of component (a), of a specific | CIBA SPECIALTY CHEMICALS CORP. (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1366116-B1 | POLYPROPYLENE RESIN COMPOSITIONS | CIBA SC HOLDING AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| US-20040063830-A1 | Crystallizable polypropylene homopolymer, random copolymer, alternating or segmented copolymer, block copolymer or a blend of polypropylene with another synthetic polymer, and b) 0.001 to 5% relative to the weight of component (a), of a specific | CIBA SPECIALTY CHEMICALS CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885ALDH1A1 451/4885MEN1 4876/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | SCD 1/4885ALDH1A1 451/4885MEN1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.